The Trump Administration has signaled a willingness to entertain arguments for removing the regulatory obstacles hampering the execution of value-based contracts for pharmaceuticals, Novartis AG CEO Joseph Jimenez said during a Duke Margolis Center for Health Policy workshop Feb. 9.
Jimenez was referring to FDA restrictions on communications between manufacturers and payers, a lack of legal “safe harbors” from federal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?